| Original language | English (US) |
|---|---|
| Pages (from-to) | e1046-e1081 |
| Journal | Circulation |
| Volume | 139 |
| Issue number | 25 |
| DOIs | |
| State | Published - Jun 18 2019 |
Keywords
- AHA Scientific Statements
- Guidelines
- biomarkers, coronary artery calcium score
- cardiovascular disease
- cholesterol, LDL-cholesterol
- diabetes mellitus
- drug therapy
- ezetimibe
- hydroxymethylglutaryl-CoA reductase inhibitors/statins
- hypercholesterolemia
- lipids
- patient compliance
- pharmacological
- primary prevention
- proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors
- risk assessment
- risk reduction discussion
- risk treatment discussion, secondary prevention
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Cite this
}
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol : Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. / Grundy, Scott M.; Stone, Neil J.; Bailey, Alison L.; Beam, Craig; Birtcher, Kim K.; Blumenthal, Roger S.; Braun, Lynne T.; de Ferranti, Sarah; Faiella-Tommasino, Joseph; Forman, Daniel E.; Goldberg, Ronald; Heidenreich, Paul A.; Hlatky, Mark A.; Jones, Daniel W.; Lloyd-Jones, Donald M; Lopez-Pajares, Nuria; Ndumele, Chiadi E.; Orringer, Carl E.; Peralta, Carmen A.; Saseen, Joseph J.; Smith, Sidney C.; Sperling, Laurence; Virani, Salim S.; Yeboah, Joseph.
In: Circulation, Vol. 139, No. 25, 18.06.2019, p. e1046-e1081.Research output: Contribution to journal › Article
TY - JOUR
T1 - 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
T2 - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
AU - Grundy, Scott M.
AU - Stone, Neil J.
AU - Bailey, Alison L.
AU - Beam, Craig
AU - Birtcher, Kim K.
AU - Blumenthal, Roger S.
AU - Braun, Lynne T.
AU - de Ferranti, Sarah
AU - Faiella-Tommasino, Joseph
AU - Forman, Daniel E.
AU - Goldberg, Ronald
AU - Heidenreich, Paul A.
AU - Hlatky, Mark A.
AU - Jones, Daniel W.
AU - Lloyd-Jones, Donald M
AU - Lopez-Pajares, Nuria
AU - Ndumele, Chiadi E.
AU - Orringer, Carl E.
AU - Peralta, Carmen A.
AU - Saseen, Joseph J.
AU - Smith, Sidney C.
AU - Sperling, Laurence
AU - Virani, Salim S.
AU - Yeboah, Joseph
PY - 2019/6/18
Y1 - 2019/6/18
KW - AHA Scientific Statements
KW - Guidelines
KW - biomarkers, coronary artery calcium score
KW - cardiovascular disease
KW - cholesterol, LDL-cholesterol
KW - diabetes mellitus
KW - drug therapy
KW - ezetimibe
KW - hydroxymethylglutaryl-CoA reductase inhibitors/statins
KW - hypercholesterolemia
KW - lipids
KW - patient compliance
KW - pharmacological
KW - primary prevention
KW - proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors
KW - risk assessment
KW - risk reduction discussion
KW - risk treatment discussion, secondary prevention
UR - http://www.scopus.com/inward/record.url?scp=85058498879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058498879&partnerID=8YFLogxK
U2 - 10.1161/CIR.0000000000000624
DO - 10.1161/CIR.0000000000000624
M3 - Article
VL - 139
SP - e1046-e1081
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 25
ER -